Terms: = Uterine cancer AND FUBP1, FBP, 8880, ENSG00000162613, FUBP AND Treatment
3 results:
1. The expression and clinical value of LRP11, fubp1 and TET1 in cervical cancer.
Zhao X; Li S; Wen J; Li Y
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):80-84. PubMed ID: 37715422
[TBL] [Abstract] [Full Text] [Related]
2. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S; Kojima Y; Yoshida H; Takamizawa S; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Saito A; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Ohe Y; Yonemori K
J Gynecol Oncol; 2022 Nov; 33(6):e82. PubMed ID: 36245230
[TBL] [Abstract] [Full Text] [Related]
3. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract] [Full Text] [Related]
